| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 06/14/2006 | EP1667522A2 Modified oligonucleotides for telomerase inhibition |
| 06/14/2006 | EP1404353A4 Methods of using a hyaluronan receptor |
| 06/14/2006 | EP1379650B1 Preferred segments of neural thread protein and methods of using the same |
| 06/14/2006 | EP1309703B1 Kallikrein gene |
| 06/14/2006 | EP1278529B1 Therapeutic uses for mesenchymal stromal cells |
| 06/14/2006 | EP1032696B1 Vector for tissue-specific replication and gene expression |
| 06/14/2006 | EP0964869B1 Methods and compositions for the treatment of neoplastic diseases |
| 06/14/2006 | EP0956360B1 Poxvirus-based expression vectors containing heterologous inserts derived from lentiviruses |
| 06/14/2006 | EP0928135B1 System for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment |
| 06/14/2006 | DE19941897B4 IL-6 Rezeptor-Protein, Beta-Kette (gp130) des IL-6 Rezeptor-Proteins, für diese Proteine kodierende DNA, davon abgeleitete RNA, Peptid mit den Aminosäuren 771-811 dieser Beta-Kette oder Teilen davon und deren Verwendungen IL-6 receptor protein beta-chain (gp130) of the IL-6 receptor protein, DNA encoding for these proteins, derived RNA, peptide with the amino acids 771-811 of the beta-chain or parts thereof and their uses |
| 06/14/2006 | DE102004059792A1 Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Nukleinsäure-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform A multiparticulate pharmaceutical form comprising mucoadhesively formulated nucleic acid active ingredients, and a process for preparing the drug form |
| 06/14/2006 | CN1788088A Mutant vesicular stomatitis viruses and use thereof |
| 06/14/2006 | CN1788086A Antisense oligonucleotides (ODN) against smad7 and uses in medical field thereof |
| 06/14/2006 | CN1788081A Anti cancer target direction adjustable gene-virus and structure method thereof |
| 06/14/2006 | CN1788017A Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions |
| 06/14/2006 | CN1787840A Drug for treating hemophilia and method of treating hemophilia using the same |
| 06/14/2006 | CN1787832A Method of treating inflammtory disease associated with bone destruction |
| 06/14/2006 | CN1786167A Polypeptide of anti HIV virus and its coding gene and application |
| 06/14/2006 | CN1785432A Chromatin peptide medicinal molecule for sealing MYC cell proliferation path |
| 06/14/2006 | CN1259422C Peptides derived from attachment (G) protein of respiratory syncytial virus |
| 06/14/2006 | CN1259418C Coding recombinant adenoviruses for iodine specific transport protein |
| 06/14/2006 | CN1259106C Preparation of target gene virus medicine against cancers |
| 06/13/2006 | US7060871 Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function |
| 06/13/2006 | US7060868 Autoimmune disease model animal |
| 06/13/2006 | US7060809 Locked nucleic acid units may be used in a wide variety of applications, such as PCR primers, sequencing, synthesis of antisense oligonucleotides, diagnostics and the like |
| 06/13/2006 | US7060690 For therapy of cancer |
| 06/13/2006 | US7060688 A gene therapy for cancers, comprising a cancer suppressing gene; genetic engineering, duplicated gene, cloned gene |
| 06/13/2006 | US7060687 Live vaccines for allergy treatment |
| 06/13/2006 | US7060504 High mobility group proteins; diagnostic monitoring the severity or potential lethality of sepsis or septic shock, measuring the serum protein concentration of patient, treating weight loss or obesity |
| 06/13/2006 | US7060500 Single-stranded oligodeoxynucleotide mutational vectors |
| 06/13/2006 | US7060499 causes recombination reaction between two mutant FRT sequences having an identical sequence to each other but does not cause recombination reaction with a wild-type FRT sequence, in the presence of FLP recombinase |
| 06/13/2006 | US7060498 Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
| 06/13/2006 | US7060449 Method of preparing GALR2 receptors composition |
| 06/13/2006 | US7060265 Cloning and recombinant production of polistinae venom enzymes, such as phospholipase and hyaluronidase, and immunological therapies based thereon |
| 06/13/2006 | CA2155434C Prohormone convertase transformed cells and polypeptide synthesis |
| 06/08/2006 | WO2006060790A2 Neoadjuvant genetic compositions and methods |
| 06/08/2006 | WO2006060649A2 Therapeutic antisense oligonucleotide composition for the treatment of inflammatory bowel disease |
| 06/08/2006 | WO2006060641A2 Methods for targeted delivery of genetic material to the liver |
| 06/08/2006 | WO2006060598A2 RNA INTERFERENCE MEDIATED INHIBITION OF INTERLEUKIN AND INTERLEUKIN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 06/08/2006 | WO2006060182A2 HIGHLY BRANCHED HK PEPTIDES AS EFFECTIVE CARRIERS OF siRNA |
| 06/08/2006 | WO2006059785A1 Development of bioactive agent using dendritic cell differentiation-inducing factor |
| 06/08/2006 | WO2006059777A1 Remedy for alzheimer’s disease |
| 06/08/2006 | WO2006059769A1 Method of diagnosing malignant lymphoma and estimating the prognosis thereof |
| 06/08/2006 | WO2006059637A1 Agent for diagnosing, preventing and treating adhesion with the use of ccr8 inhibitor |
| 06/08/2006 | WO2006059507A1 11β-HSD1 ANTISENSE COMPOUND |
| 06/08/2006 | WO2006059081A2 Methods of treatment using melanopsin |
| 06/08/2006 | WO2006058489A1 A recombinant adeno-associated virus expressing human antisense gene cyp2j2 and its preparation methods |
| 06/08/2006 | WO2006044842A3 Pancreatic islet beta-cell-like macrophages and methods to produce them |
| 06/08/2006 | WO2006026485A3 Modulation of hif1-beta expression |
| 06/08/2006 | WO2006020676A3 Antisense modulation of apolipoprotein b expression |
| 06/08/2006 | WO2006014234A3 Novel recombinant poxvirus composition and uses thereof |
| 06/08/2006 | WO2006002394A3 Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| 06/08/2006 | WO2005092069A3 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof |
| 06/08/2006 | WO2005027833A3 Compound and method for treating androgen-independent prostate cancer |
| 06/08/2006 | WO2005002527A3 Sirt1 modulation of adipogenesis and adipose function |
| 06/08/2006 | US20060123502 Assay methods for identifying RE2-like antagonists, methods of use, and non-human transgenic animals |
| 06/08/2006 | US20060123498 Paks as modifiers of the chk pathway and methods of use |
| 06/08/2006 | US20060122374 Albumin-fused anti-angiogenesis peptides |
| 06/08/2006 | US20060122372 Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications |
| 06/08/2006 | US20060122142 DNA vaccines for farm animals, in particular bovines and porcines |
| 06/08/2006 | US20060122141 For treatment of endocrine-regulated tumors, for example, breast, prostate, ovarian and colon cancers |
| 06/08/2006 | US20060122140 In Vitro and in vivo silencing of human c-myc oncogene expression by poly-DNP-RNA |
| 06/08/2006 | US20060122139 Inducible systems and methods for controlling siRNA expression |
| 06/08/2006 | US20060122138 Modulators of EphA2 and EphrinA1 for the treatment of fibrosis-related disease |
| 06/08/2006 | US20060122137 5'-methylpyrimidine and 2'-O-methyl ribonucleotide modified double-stranded ribonucleic acid molecules |
| 06/08/2006 | US20060122136 Effective and stable DNA enzymes |
| 06/08/2006 | US20060122135 Cloning and expression of a novel member of the Glial cell-line derived neurotrophic factors (GDNF); Parkinson's , Alzheimer's , Huntington's, Creutzfeld-Jacob diseases, neuropathic pain; acute brain injury, multiple sclerosis, amyotrophic lateral sclerosis, peripheral nerve trauma; cancer |
| 06/08/2006 | US20060122134 double-stranded decoy oligonucleotide; atherosclerosis; acts as a competitive inhibitor (or rather neutralisation) of a natural core-binding sequence of a DNA-binding protein or protein complex thereby blocks the expression of the eNOS |
| 06/08/2006 | US20060122133 Antisense modulation of vegf co-regulated chemokine-1 expression |
| 06/08/2006 | US20060122132 Use of murine genomic regions identified to be involved in tumor developement for the development of anti-cancer drugs and diagnosis of cancer |
| 06/08/2006 | US20060122131 Methods for blocking adipocyte differentiation and triglyceride accumulation with transcription factor dp-1 inhibitors |
| 06/08/2006 | US20060122130 Method for rendering a system immunologically compatible utilizing a nucleic acid construct, a nucleic acid construct for inhibiting or regulating the function of an immune response (Ir) gene and an immunologically compatible system containing a nucleic acid construct for inhibiting or regulating the function of an immune response (Ir) gene |
| 06/08/2006 | US20060122119 Peptides for use in antitumor immunotherapy |
| 06/08/2006 | US20060122118 Therapeutic compositions and methods of using same |
| 06/08/2006 | US20060122112 Method for preventing or treating osteosarcoma |
| 06/08/2006 | US20060122111 Regeneration and neogenesis of retinal visual cell otx2 gene |
| 06/08/2006 | US20060122105 Method of improing the growth performance of an animal |
| 06/08/2006 | US20060122096 Reversible modification of amine-containing compounds |
| 06/08/2006 | US20060121554 Regulation of human RTA-like GPCR |
| 06/08/2006 | US20060121522 Stimulating an immune response in human or animal, by administering a gene which LACKS A FUNCTIONAL VHS GENE, lacks a functional gene encoding ICP47, COMPRISES A FUNCTIONAL UL43 GENE, to infect DENDRITIC CELLS; increase gene expression on the surface of tumour cells; protection against cancer; vaccines |
| 06/08/2006 | US20060121514 Prostacyclin-stimulating Factor-2 |
| 06/08/2006 | US20060121498 Enzymes involved in apoptosis |
| 06/08/2006 | US20060121465 Sgk and nedd used as diagnostic and therapeutic targets |
| 06/08/2006 | US20060121456 Isolated human ras-like proteins acid molecules encoding these human ras-like proteins, and uses thereof |
| 06/08/2006 | US20060121454 diagnosis and treatment of carcinomas, especially breast cancers |
| 06/08/2006 | US20060121122 Process for producing microcapsule |
| 06/08/2006 | US20060121105 Method of lipid structure preparation |
| 06/08/2006 | US20060121047 Use of hmgb polypetides for increasing immune responses |
| 06/08/2006 | US20060121041 Gpcs as modifiers of the irrtk p21 pathways and methods of use |
| 06/08/2006 | US20060121040 Compositions and methods for treating neuroendocrine tumors |
| 06/08/2006 | US20060121039 Use of agents that prevent the generation of amyloid-like proteins and/or drusen, and/or use of agents that promote sequestration and/or degradation of, and/or prevent the neurotoxic effects of such proteins in the treatment of macular degeneration |
| 06/08/2006 | US20060121035 Methods for treating diabetes |
| 06/08/2006 | US20060121030 Use of cd 137 antagonists for the treatment of tumors |
| 06/08/2006 | US20060121029 Method and composition for regulating the activity of regulatory t cells |
| 06/08/2006 | US20060121025 VEGF-related protein |
| 06/08/2006 | US20060121023 Method to decrease nonspecific staining by Cy5 |
| 06/08/2006 | US20060121014 Cell culture comprises astrocytes with induced antioxidant response element (ARE) mediated transcription; Alzheimer's disease, Huntington's disease, Parkinson's disease |
| 06/08/2006 | US20060121013 Use of negative regulatory elements for the neurospecific expression of transgenes |
| 06/08/2006 | US20060121012 An implantable device coated with a matrix-bound ligand that binds the cell membrane markers of genetically altered mammalian cells and express and secrete at least one therapeutic gene product; vascular diseases; anticarcinogenic agents |
| 06/08/2006 | US20060121011 Combination gene delivery vehicles |